Cargando…
Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity
[Image: see text] Alterations in visceral adipose tissue (VAT) are closely linked to cardiometabolic abnormalities. The aim of this work is to define a metabolic signature in VAT of insulin resistance (IR) dependent on, and independent of, obesity. An untargeted UPLC-Q-Exactive metabolomic approach...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631729/ https://www.ncbi.nlm.nih.gov/pubmed/33760621 http://dx.doi.org/10.1021/acs.jproteome.0c00918 |
_version_ | 1784607621280432128 |
---|---|
author | Palau-Rodriguez, Magalí Marco-Ramell, Anna Casas-Agustench, Patricia Tulipani, Sara Miñarro, Antonio Sanchez-Pla, Alex Murri, Mora Tinahones, Francisco J. Andres-Lacueva, Cristina |
author_facet | Palau-Rodriguez, Magalí Marco-Ramell, Anna Casas-Agustench, Patricia Tulipani, Sara Miñarro, Antonio Sanchez-Pla, Alex Murri, Mora Tinahones, Francisco J. Andres-Lacueva, Cristina |
author_sort | Palau-Rodriguez, Magalí |
collection | PubMed |
description | [Image: see text] Alterations in visceral adipose tissue (VAT) are closely linked to cardiometabolic abnormalities. The aim of this work is to define a metabolic signature in VAT of insulin resistance (IR) dependent on, and independent of, obesity. An untargeted UPLC-Q-Exactive metabolomic approach was carried out on the VAT of obese insulin-sensitive (IS) and insulin-resistant subjects (N = 11 and N = 25, respectively) and nonobese IS and IR subjects (N = 25 and N = 10, respectively). The VAT metabolome in obesity was defined among other things by changes in the metabolism of lipids, nucleotides, carbohydrates, and amino acids, whereas when combined with high IR, it affected the metabolism of 18 carbon fatty acyl-containing phospholipid species. A multimetabolite model created by glycerophosphatidylinositol (18:0); glycerophosphatidylethanolamine (18:2); glycerophosphatidylserine (18:0); and glycerophosphatidylcholine (18:0/18:1), (18:2/18:2), and (18:2/18:3) exhibited a highly predictive performance to identify the metabotype of “insulin-sensitive obesity” among obese individuals [area under the curve (AUC) 96.7% (91.9–100)] and within the entire study population [AUC 87.6% (79.0–96.2)]. We demonstrated that IR has a unique and shared metabolic signature dependent on, and independent of, obesity. For it to be used in clinical practice, these findings need to be validated in a more accessible sample, such as blood. |
format | Online Article Text |
id | pubmed-8631729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-86317292021-12-01 Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity Palau-Rodriguez, Magalí Marco-Ramell, Anna Casas-Agustench, Patricia Tulipani, Sara Miñarro, Antonio Sanchez-Pla, Alex Murri, Mora Tinahones, Francisco J. Andres-Lacueva, Cristina J Proteome Res [Image: see text] Alterations in visceral adipose tissue (VAT) are closely linked to cardiometabolic abnormalities. The aim of this work is to define a metabolic signature in VAT of insulin resistance (IR) dependent on, and independent of, obesity. An untargeted UPLC-Q-Exactive metabolomic approach was carried out on the VAT of obese insulin-sensitive (IS) and insulin-resistant subjects (N = 11 and N = 25, respectively) and nonobese IS and IR subjects (N = 25 and N = 10, respectively). The VAT metabolome in obesity was defined among other things by changes in the metabolism of lipids, nucleotides, carbohydrates, and amino acids, whereas when combined with high IR, it affected the metabolism of 18 carbon fatty acyl-containing phospholipid species. A multimetabolite model created by glycerophosphatidylinositol (18:0); glycerophosphatidylethanolamine (18:2); glycerophosphatidylserine (18:0); and glycerophosphatidylcholine (18:0/18:1), (18:2/18:2), and (18:2/18:3) exhibited a highly predictive performance to identify the metabotype of “insulin-sensitive obesity” among obese individuals [area under the curve (AUC) 96.7% (91.9–100)] and within the entire study population [AUC 87.6% (79.0–96.2)]. We demonstrated that IR has a unique and shared metabolic signature dependent on, and independent of, obesity. For it to be used in clinical practice, these findings need to be validated in a more accessible sample, such as blood. American Chemical Society 2021-03-24 2021-05-07 /pmc/articles/PMC8631729/ /pubmed/33760621 http://dx.doi.org/10.1021/acs.jproteome.0c00918 Text en © 2021 American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Palau-Rodriguez, Magalí Marco-Ramell, Anna Casas-Agustench, Patricia Tulipani, Sara Miñarro, Antonio Sanchez-Pla, Alex Murri, Mora Tinahones, Francisco J. Andres-Lacueva, Cristina Visceral Adipose Tissue Phospholipid Signature of Insulin Sensitivity and Obesity |
title | Visceral Adipose
Tissue Phospholipid Signature of
Insulin Sensitivity and Obesity |
title_full | Visceral Adipose
Tissue Phospholipid Signature of
Insulin Sensitivity and Obesity |
title_fullStr | Visceral Adipose
Tissue Phospholipid Signature of
Insulin Sensitivity and Obesity |
title_full_unstemmed | Visceral Adipose
Tissue Phospholipid Signature of
Insulin Sensitivity and Obesity |
title_short | Visceral Adipose
Tissue Phospholipid Signature of
Insulin Sensitivity and Obesity |
title_sort | visceral adipose
tissue phospholipid signature of
insulin sensitivity and obesity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631729/ https://www.ncbi.nlm.nih.gov/pubmed/33760621 http://dx.doi.org/10.1021/acs.jproteome.0c00918 |
work_keys_str_mv | AT palaurodriguezmagali visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT marcoramellanna visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT casasagustenchpatricia visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT tulipanisara visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT minarroantonio visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT sanchezplaalex visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT murrimora visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT tinahonesfranciscoj visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity AT andreslacuevacristina visceraladiposetissuephospholipidsignatureofinsulinsensitivityandobesity |